ENCORE 601: ENT in combination with PEMBRO in Advanced Melanoma Patients

Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of his presentation, Abstract #9529 ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO... Author: ASCO2017 Added: 06/02/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts